EISAI CO LTD

How Eisai’s Lecanemab review shows the cost‑benefit gap in Alzheimer’s drugs—and why Germany’s value‑based reimbursement forces pharma to prove real clinical value.

Read how Eisai’s orphan‑drug designation for E2086 could unlock Japan’s growing narcolepsy market and the cost‑benefit challenges ahead.

Explore how Eisai’s new co‑exclusive deals with Henlius and Fosun bolster its anti‑PD‑1 pipeline, mitigate patent cliffs, and aim for a 10‑15 % sales lift by 2029.

Discover how Eisai’s EMA IV‑maintenance and FDA SC‑autoinjector approvals could improve Alzheimer’s therapy access, boost patient adherence, and expand market reach.

Priority review for Eisai’s Leqembi autoinjector accelerates at‑home Alzheimer’s treatment, boosting patient convenience, potential market share, and strategic momentum.

Explore how Eisai’s diversified portfolio and breakthrough trials are boosting investor confidence, with highlights on Alzheimer’s, oncology and neuroinflammation research.

Explore Eisai’s dual pharma‑and‑agro strategy, growth prospects, and risks—from oncology trials to green pesticides—insights for investors.

New Eisai data shows anti‑tau antibody etalanetug reduces tau PET signal in some DIAD patients and a subcutaneous Leqembi launch targets Japan, boosting AD treatment access and convenience.

Discover how Eis Co.’s subcutaneous Leqembi (lecanemab) filings in Japan & the U.S. aim to accelerate Alzheimer’s therapy access, boost market share, and secure IP protection.

Read how Eisai’s Leqembi Iqlik could change Alzheimer’s care with at‑home injections and the implications for FDA approval, pricing, and market growth.